室间隔缺损患儿封堵术前后血浆N末端B型利钠肽原和左心室Tei指数变化的意义

Objective To explore the implication of the dynamic changes of plasma N-terminal proB-type natriuretic peptide (NT-proBNP) level and Tei index of left ventricle (LV) in children with ventricular septal defect(VSD) treated by transcatheter closure. Methods Sixty children with VSD treated by transcatheter closure with VSD occluder (Group VSD) and 30 healthy children (Group C) were included in this study. The plasma concentration of NT-proBNP, Tei index of LV and left ventricle ejection fraction (LVEF) were measured in Group C and at before, 5th minute, 4th hour, 1st month, 3rd month and 6th month after VSD closure in Group VSD. Results ( 1 ) The concentration of plasma NT-proBNP was significantly increased in children with VSD before transcatheter closure compared with Group C [(229.45 ±57.75 ) ng/L vs. (99. 21 ± 46. 86) ng/L,P ＜ 0. 01], significantly increased at 5th minute and 24th hour after transcatheter closure[( 356.27 ± 96. 78 ) ng/L and ( 356. 38 ± 91.95 ) ng/L vs. ( 229. 45 ± 57.75 ) ng/L, all P ＜0. 01], and significantly decreased at 1st month, 3rd months and 6th months after transcatheter closure [( 131.33 ± 34. 79 ) ng/L, (96. 56 ± 31.55 ) ng/L and ( 93. 39 ± 29. 46 ) ng/L vs. ( 229. 45 ± 57.75 ) ng/L,P＜0.05 or P＜0. 01]. (2) The Tei indexes of LV in Group VSD before transcatheter closure were significantly higher than in Group C (0. 45 ± 0. 05 vs. 0. 33 ± 0. 08, P ＜ 0. 01 ) and Tei index was significantly increased at 24th hour, 1 st month after transcatheter closure (P ＜ 0. 01 ) while significantly decreased at 3rd and 6th month compared with those before transcatheter closure (0. 34 ±0. 07 and 0. 34 ±±0. 06 vs. 0. 45 ±0. 05 ,all P ＜0. 01 ). (3) There is a positive correlation between the changes of the plasma concentration of NT-proBNP and the change of Tei index of LV before and after transcatheter closure (r = 0. 653, P ＜ 0. 05).Conclusion Tei index of LV and NT-proBNP can monitor cardiac function changes in children with VSD before and after transcatheter closure.     

室间隔缺损患儿封堵术前后血浆N末端B型利钠肽原和左心室Tei指数变化的意义

Objective To explore the implication of the dynamic changes of plasma N-terminal proB-type natriuretic peptide (NT-proBNP) level and Tei index of left ventricle (LV) in children with ventricular septal defect(VSD) treated by transcatheter closure. Methods Sixty children with VSD treated by transcatheter closure with VSD occluder (Group VSD) and 30 healthy children (Group C) were included in this study. The plasma concentration of NT-proBNP, Tei index of LV and left ventricle ejection fraction (LVEF) were measured in Group C and at before, 5th minute, 4th hour, 1st month, 3rd month and 6th month after VSD closure in Group VSD. Results ( 1 ) The concentration of plasma NT-proBNP was significantly increased in children with VSD before transcatheter closure compared with Group C [(229.45 ±57.75 ) ng/L vs. (99. 21 ± 46. 86) ng/L,P ＜ 0. 01], significantly increased at 5th minute and 24th hour after transcatheter closure[( 356.27 ± 96. 78 ) ng/L and ( 356. 38 ± 91.95 ) ng/L vs. ( 229. 45 ± 57.75 ) ng/L, all P ＜0. 01], and significantly decreased at 1st month, 3rd months and 6th months after transcatheter closure [( 131.33 ± 34. 79 ) ng/L, (96. 56 ± 31.55 ) ng/L and ( 93. 39 ± 29. 46 ) ng/L vs. ( 229. 45 ± 57.75 ) ng/L,P＜0.05 or P＜0. 01]. (2) The Tei indexes of LV in Group VSD before transcatheter closure were significantly higher than in Group C (0. 45 ± 0. 05 vs. 0. 33 ± 0. 08, P ＜ 0. 01 ) and Tei index was significantly increased at 24th hour, 1 st month after transcatheter closure (P ＜ 0. 01 ) while significantly decreased at 3rd and 6th month compared with those before transcatheter closure (0. 34 ±0. 07 and 0. 34 ±±0. 06 vs. 0. 45 ±0. 05 ,all P ＜0. 01 ). (3) There is a positive correlation between the changes of the plasma concentration of NT-proBNP and the change of Tei index of LV before and after transcatheter closure (r = 0. 653, P ＜ 0. 05).Conclusion Tei index of LV and NT-proBNP can monitor cardiac function changes in children with VSD before and after transcatheter closure.     

磷酸肌酸钠改善老年慢性心力衰竭患者左心功能的观察

目的 观察磷酸肌酸钠对老年慢性心功能不全患者的左心功能的治疗效果.方法 我科收治的172例老年慢性心功能不全患者,抽签随机分为治疗组和对照组各86例,对照组给予常规抗心力衰竭治疗,治疗组在常规治疗基础上加用磷酸肌酸钠,治疗4周.评价两组患者心功能改善情况及对浆氨基末端-脑钠肽前体(NT-proBNP)的影响.结果治疗组左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)改善程度优于对照组,差异有统计学意义(均P＜0.05);血浆NT-proBNP下降水平高于对照组,分别为治疗前(956.4±644.2)pmol/L和(973.6±639.8)pmol/L,治疗后(414.5±163.8)pmol/L和(719.3±477.5)pmol/L,差异有统计学意义(均P＜0.05).结论 磷酸肌酸钠能改善老年慢性心功能不全患者的心功能,降低血浆NT-proBNP水平.

Abstract：

Objective To observe the clinical effects of phosphocreatine treatment on left ventricular function and on amino-terminal pro-brain natriuretic peptide (NT-proBNP) level in elderly patients with chronic heart failure. Methods In our department, the 172 elderly patients with chronic heart failure were randomly divided into treatment group and control group (n= 86, each).The control group received routine anti-heart failure treatment. The treatment group received conventional therapy plus creatine phosphate sodium for 4 weeks. The cardiac function was evaluated and the NT-proBNP level was measured in all subjects. Results Four weeks after treatment, the improvements of left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic dimension (LVEDD) were better in treatment group than in control group (all P＜0.05). The plasma NT-proBNP level decreased significantly in treatment group as compared with control group [before treatment: (956.4 ± 644.2) pmol/L and (973.6 ±639.8) pmol/L; after treatment: (414. 5 ± 163.8 ) pmol/L and ( 719.3 ± 477. 5 ) pmol/L, all P＜0. 05]. Conclusions Phosphocreatine could improve left ventricular function and decrease plasma NT-proBNP level in elderly patients with chronic heart failure.     

抗炎与抗氧化联合治疗在卒中急性期的应用

目的 探讨联合抗炎、抗氧化治疗在卒中急性期的作用.方法 将128例急性缺血性卒中患者随机分为对照组(71例)与联合治疗组(57例),检测治疗前后血浆标志物水平,评价治疗前后神经功能及生活能力,进行组间及组内比较,观察联合治疗对急性期血浆标志物及早期临床预后的影响.结果 治疗前联合治疗组基质金属蛋白酶(MMP)-9水平[(3.23±0.99)ng/L]高于对照组[(2.82±1.21)ng/L,P＜0.05];联合治疗组氧化低密度脂蛋白(ox-LDL)抗体水平治疗前[(0.08±0.01)U/m1]高于治疗后[(0.07±0.01)U/ml,P＜0.05];对照组治疗前美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分[(5.76±6.61)分比高于治疗后(4.22±5.45)分,P＜0.05].结论 联合治疗可以降低缺血性卒中急性期患者血浆MMP-9及ox-LDL抗体水平,但未明显改善早期预后.

Abstract：

Objective Research the effect of anti-inflammatory and anti-oxidation drugs on acute stroke patients. Methods 128 patients with acute ischemic stroke are divided into two groups- combined treatment group (71) and control (57). Test serum biomarkers and evaluate neurological function and living ability before and after therapy, compare between groups and intra-group. To observe the effects of combined therapy on serum biomarkers and prognosis in acute stage. Results ( 1 ) MMP-9 of combined treatment group (3.23 ±0. 99) ng/L is higher than control (2. 82 ± 4. 21 )ng/L before therapy (P ＜0. 05). (2) The level of pre-treatment ox-LDL-Ab in combined treatment group ( 0. 08 ± 0. 01 ) U/ml higher than posttreatment (0. 07 ±0. 01 ) U/ml (P ＜ 0. 05 ). The level of pre-treatment NIHSS in control group (5.76 ±6.61) score higher than post-treatment (4.22 ±5.45) score,P＜0.05. Conclusion Combined treatment can degrade serum MMP-9 and ox-LDL in acute ischemic stroke patients, but it can't obviously improve the earlier prognosis.     

高原心脏病心功能指数与B型利钠肽相关研究

目的 通过观察高原心脏病心力衰竭患者心功能综合指数(Tei)和外周血N末端B型利钠肽前体(NT-proBNP)水平,探讨右室Tei指数、NT-proBNP在高原心脏病中的诊断价值.方法 对2008-2010年在解放军第二十二医院心内科住院的34例高原心脏病患者进行超声指标Tei指数和NT-proBNP水平测定,并进行相关性比较.结果 根据超声心动图征象将高原心脏病患者分为A、B两组,A组与健康对照组(C组)相比,肺动脉收缩压[86.6 mm Hg比9.7 mm Hg(1 mum Hg =0.133kPa)]、右室Tei指数(0.90比0.33)均显著增高(P＜0.05);B组C组相比,肺动脉收缩压(57.1比9.72) mm Hg、右室Tei指数(0.78比0.33)显著增高(P＜0.05);A、B两组患者外周血NT-proBNP水平分别为(1246.8±512.6)ng/L、( 637.3±351.3) ng/L,均显著高于C组(98.6±21.7) ng/L水平,P＜0.05.结论 右心室Tei指数和NT-proBNP浓度是反映右心整体功能的较敏感指标,两者对于诊断高原心脏病具有一定的临床意义.     

非小细胞肺癌患者呼出气冷凝液中p53蛋白检测的临床意义

目的 研究非小细胞肺癌(NSCLC)患者呼出气冷凝液(EBC)中p53蛋白检测的临床意义.方法 收集98例NSCLC患者的EBC和血浆,应用双抗体夹心ABC-ELISA法检测EBC和血浆中p53蛋白表达水平,并与98名健康对照者测定值比较.用免疫组化法检测98例NSCLC患者手术切除标本癌组织中p53蛋白表达.比较肺癌组中不同分型、分期、病理类型、肿瘤大小以及有无淋巴结转移、吸烟史者EBC和血浆中p53蛋白水平和癌组织p53蛋白阳性表达率.应用 ROC曲线分析肺癌组血浆及EBC的p53蛋白诊断肺癌的特异性及敏感性.结果 ①肺癌组EBC中p53蛋白测定值高于健康对照组[(233.99±7.91)ng/L vs(130.26±4.73)ng/L,P＜0.01];肺癌组血浆p53蛋白测定值高于健康对照组[(292.58±8.79)ng/L vs(141.66±3.33)ng/L,P＜0.01].②肺癌组中央型患者EBC中p53蛋白测定值高于周围型患者[(248.22±8.58)ng/L vs(215.78±6.61)ng/L,P＜0.05].③免疫组化阳性组EBC中p53蛋白测定值高于阴性组「(249.77±8.07)ng/L vs(216.86±7.44)ng/L,P＜0.05].④肺癌组中吸烟者血浆p53蛋白测定值高于无吸烟者[(310.18±9.04)ng/L vs(254.55±6.91)ng/L,P＜0.01].⑤癌组织p53蛋白阳性表达率为47.96%(47/98).⑥血浆p53蛋白对于肺癌的诊断的敏感性为95.90%.特异性为90.04%;EBC p53蛋白埘于肺癌的诊断的敏感性为92.90%,特异性为79.59%;肺癌患者p53蛋白诊断最佳参考临界值血浆为175.68 ng/L,EBC为166.26 ng/L.结论 NSCLC患者中EBC p53蛋白的检测有助于肺癌的诊断.

Abstract：

Objective To study the clinical significance of the detection of p53 protein in exhaled breath condensate (EBC) of patients with non-small cell lung cancer (NSCLC). Methods EBC and plasma of 98 patients with NSCLC were collected,p53 protein expression in EBC and plasma was detected by enzyme-linked immunosorbent assay,and the data were compared with those of 98 healthy controls. p53 protein expression in cancer tissue of 98 patients with NSCLC was detected by immunohistochemistry. p53 protein expression in EBC and plasma and positive expression rate of p53 protein in cancer tissue were compared among patients with different lung cancer type,stage,histologic type,tumor size,and lymph node metastasis,smoking history. The specificity and sensitivity of diagnosis of p53 protein in patients with NSCLC were analyzed by ROC curve. Results ① The level of p53 protein in EBC of patients with NSCLC was significantly higher than that in healthy control group [(233.99±7.91) ng/L vs ( 130. 26 ± 4. 73) ng/L,P ＜0. 01]. The level of p53 protein in serum of patients with NSCI.C was significantly higher than that in healthy control group [(292. 58 ± 8. 79) ng/L vs (141. 66±3. 33) ng/L,P ＜0. 01]. ② The level of p53 protein in EBC of patients with central lung cancer was higher than that in patients with peripheral lung cancer [(248. 22 ± 8. 58) ng/L vs (215. 78 ± 6.61) ng/L,P＜0. 01]. ③The level of p53 protein in EBC of patients with positive immunostaining group was higher than that in negative group [(249.77 ± 8.07) ng/L vs (216.86 ± 7.44) ng/L,P ＜ 0. 05]. ④The level of p53 protein in serum of smokers was significantly higher than that in non-smokers [(310.18 ± 9.04) ng/L vs (254. 55 ± 6. 91) ng/L,P ＜0. 01]. ⑤The positive expression rate of p53 protein in cancer tissue was 47. 96% (47/98). ⑥The sensitivity and specificity of diagnosis of p53 protein were 95. 90% and 90. 04% in plasma,and those were 92. 90% and 79. 59% in EBC. The cut off values of p53 protein were respectively 175. 68 ng/L and 166. 26 ng/L in EBC and serum. Conclusions The detection of p53 protein in EBC of patients with NSCLC is helpful for the diagnosis of lung cancer.     

急性冠状动脉综合征患者血浆N-端脑利钠肽前体浓度与

目的 通过测定急性冠状动脉综合征患者血浆N-端脑利钠肽前体(NT-proBNP)水平并分析其与冠状动脉病变严重程度的相关性.方法 回顾性分析行冠状动脉造影检查并结合病史诊断为急性冠状动脉综合征的患者40例,另选20例冠状动脉造影检查阴性者为对照组.冠状动脉病变严重程度使用Gensini评分.急性冠状动脉综合征患者根据Gensini积分被分为Gensini积分≥30分组和＜30分组,按冠状动脉病变支数分为单只、双支和三支病变组.采用免疫定量分析仪及配套试剂测定所有患者血浆NT-proBNP水平,分析NT-proBNP与冠状动脉病变严重程度的相关性.结果 急性冠状动脉综合征组NT-proBNP水平明显高于对照组[242.56±68.16 ng/L比27.12±16.48 ng/L,P＜0.01].血浆NT-proBNP水平三支病变组高于单支病变组(P＜0.05).Gensini积分≥30分组NT-proBNP水平明显高于Gensini积分＜30分组[228.14±46.16 ng/L比127.64±32.64 ng/L,P＜0.05].血浆NT-proBNP水平与Gensini积分呈正相关(r=0.56,P＜0.05).结论 急性冠状动脉综合征患者血浆NT-proBNP水平在评价冠状动脉病变严重程度方面具有一定的临床意义.     

经导管封堵心脏人工瓣膜置换术后周围漏

目的 探讨经导管堵闭器封堵外科瓣膜置换术后人工瓣膜周围漏(PVL)的可行性、有效性和安全性.方法 回顾性分析外科瓣膜置换术后诊断为PVL的5例患者,其中主动脉瓣机械瓣置换术后PVL 2例,二尖瓣生物瓣置换术后PVL 2例,主动脉瓣和二尖瓣机械瓣置换术后二尖瓣PVL1例.封堵前后检查超声心动图以评价疗效.结果 患者均采用国产封堵器进行堵闭.2例主动脉瓣PVL封堵术后无残余;3例二尖瓣PVL堵闭术后残存微量至少量反流.其中1例主动脉瓣PVL患者介入术中出现心脏穿孔、心包填塞,经穿刺引流后痊愈.3例二尖瓣PVL患者出现术后早期溶血,于术后1～3周恢复.与术前比较,3个月随访期间左心室舒张末期内径减小[(52.2±6.8)mm比(61.1±7.2)mm,P＜0.05],肺动脉收缩压下降[(40.0±5.4)mm Hg(1 mm Hg=0.133 kPa)比(57.0±3.6)mm Hg,P＜0.05],二尖瓣PVL患者左心房内径减小[(49.0±4.3)mm比(56.0±6.3)mm,P＜0.05].结论 经导管封堵人工瓣置换术后PVL可行而且安全、有效,在具备适应证患者中可作为治疗选择.

Abstract：

Objective To evaluate the feasibility and efficacy of transcatheter closure of paravalvular leak (PVL) with Chinese-made occlder. Methods Five PVL patients were involved in this study, 2 out of the 5 patients underwent aortic mechanical valve replacements, 2 underwent mitral bioprosthetic valve replacements, and the remaining 1 underwent double mechanical valve replacement. Left ventricular end diastolic diameter, left atrial diameter and the systolic pulmonary artery pressure were assessed by echocardiography before and post the procedure. Results Complete occlusion without residual regurgitation was achieved in 2 patients with aortic PVL, for the 3 patients with mitral PVL, there was only tiny or mild mitral paraprosthetic leak remained post closure procedure. Cardiac perforation and pericardium tampenade occurred in 1 patient with aortic PVL during interventional closure and the patient recovered post emergent pericardiocentesis. Transient severe hemolysis and hemoglobinuria occurred in 3 patients with mitral PVL post closure procedure and they recovered after 1 to 3 weeks concervative therapy. During 3 months follow up, left ventricular end diastolic diameter [( 52. 2 ± 6. 8 ) mm vs. ( 61.1 ± 7.2 ) mm, P ＜0. 05], the systolic pulmonary artery pressure [(40. 0 ±5.4) mm Hg( 1 mm Hg =0. 133 kPa) vs. (57. 0 ±3.6) mm Hg, P ＜ 0. 05] and left atrial diameter of mitral PVL patient [( 49. 0 ± 4. 3 ) mm vs. ( 56. 0 ±6. 3) mm, P ＜ 0. 05] were significantly reduced compared to before closure procedure. Conclusion Percutaneous or transapical left ventricular access closure of PVL is feasible, effective and relative safe in selected patients.     

Clinical Study on Amplatzer Occluder Device to CloseVentricular Septal Defect

Objectives To evaluate the therapeutic effect of transcatheter Amplatzer device on the closure of ventricular septal defect （VSD）. Methods Among 143 patients with VSD, 135 patients with perimembrane VSD and 2 with muscular VSD aged 2.5 -28 years old, were successfully closed with Amplatzer oeeluder device by the pereutaneous guidwire through femoral artery-VSD-femoral vein route under the guidance of fluoroscopy, ventrieulography and transthoracic echocardiography （TIE）. The diameters of the VSDs were 2.3-15.7 （6.90±2.76）mm by left ventriculography. Results The success rate of transcatheter closure of VSD with Amplatzer devices was 96%（137/143）. Minimal residual amount of shunts were found in one patient, although the shunts was decreased one month after the procedure. There were one patient who had respiratory arrest during the procedure, 7 patients（5%）had conduction disturbance, 3 patients had complete left bundle branch block, 2 patients had complete right bundle branch block, 1 patient had Ⅰ degree atrial-ventricular block and 1 patient had Ⅲ degree atr/al-ventricular block during hospitalization. The diameters of the occluder ranged from 4 to 23 （9.13±3.31）mm and were symmetrical in 122 patients and asymmetrical in 15 patients. Conclusions Transcatheter closure of the perimembranous ventrieular septal defect using Amplatzer VSD occluder device is an efficient method for patients with the perimembranous VSD. The operation is simple with a high success rate and a good effect.     

血浆N末端脑利钠肽原和血清白蛋白在早期诊断不完全川崎病中的临床价值

目的 观察川崎病、不完全川崎病(IKD)和发热原因不明患儿血浆N末端脑利钠肽原(NT-proBNP)、血清白蛋白的表达水平,探讨血NT-proBNP、白蛋白水平在早期诊断IKD中的临床意义.方法 应用酶联荧光分析(ELFA)技术测定246例川崎病患儿(川崎病组)、61例IKD患儿(IKD组)及301例入院时发热原因不明患儿(发热组)人院当天血浆NT-proBNP水平,同时观察血白蛋白等水平.川崎病、IKD患儿行心电图及超声心动图检查,根据检查结果分心血管损害组及无心血管损害组.对各组间检测指标比较应用t检验或方差分析,各检测指标间关系用Pearson相关分析,对有统计学意义的NT-proBNP值进行受试者工作特征曲线(ROC)分析,获得鉴别心血管损害的最佳临界值.结果 ①川崎病组、IKD组血浆NT-proBNP水平明显高于发热组[(789.1±4.7)、(824.8±4.4)和(92.5±2.3) ng/L,F=230.736,P均＜0.05].②川崎病组、IKD组血白蛋白水平明显低于发热组[(33.9±2.8)、(33.8±3.1)和(40.8±3.6) g/L,F=355.648,P均＜0.05].③川崎病组、IKD组中心血管损害组与无心血管损害组血浆NT-proBNP水平比较,川崎病组:(2948±3) g/L(103例)和(307±3) g/L(143例);IKD组:(1454±4) g/L(38例)和(323±4) g/L(23例);差异均有统计学意义(t=16.464、4.356,P均＜0.05).④当血浆NT-proBNP水平≥933.5 ng/L时,鉴别川崎病、IKD患儿是否存在心血管损害的敏感性为88.1％,特异性为89％.⑤当血浆NT-proBNP＞250 ng/L时诊断川崎病、IKD的敏感性分别为80.9％、85.2％,特异性均为85.7％.当同时满足血浆NT-proBNP＞250 ng/L及血白蛋白＜35 g/L时诊断川崎病、IKD的敏感性分别为67.5％、70.5％,特异性均为99.7％.结论 血浆NT-proBNP水平升高(＞250 ng/L)同时伴白蛋白下降(＜35 g/L)可能是早期诊断IKD的特异性指标,以血浆NT-proBNP≥933.5 ng/L作为诊断川崎病、IKD患儿心血管损害的临界值可较好地兼顾敏感性和特异性.     

动脉导管未闭患儿介入封堵前后心率变异性及血浆肾上腺髓质素、B型利钠肽的变化

目的 探讨动脉导管未闭(PDA)患儿介入封堵术前后心率变异性及血浆肾上腺髓质素、B型利钠肽(BNP)水平的变化及临床意义.方法 选择55例PDA患儿作为PDA组,在介入封堵术前3 d及术后3 d、3个月分别检测心率变异性频域(总频谱、极低频功率、低频功率、高频功率、低频功率/高频功率)结果及血浆肾上腺髓质素、BNP水平.另选60名健康儿童作为对照组.结果 (1)与对照组比较,PDA组术前心率变异性频域总频谱、极低频功率、高频功率均较低,而低频功率/高频功率及血浆肾上腺髓质素、BNP水平均较高(均P＜0.01).(2)介入封堵术后3 d及3个月,血浆肾上腺髓质素水平均较术前明显降低(均P＜0.01),而与对照组比较差异无统计学意义.心率变异性及血浆BNP水平术后3 d与术前差异无统计学意义.与术前比较,术后3个月心率变异性频域总频谱、极低频功率、高频功率均明显升高(P＜0.01或P＜0.05),而低频功率/高频功率及血浆BNP水平明显降低(均P＜0.01).结论 心率变异性及血浆肾上腺髓质素、BNP水平在PDA介入封堵术后均改善,可作为了解PDA介入封堵术后心脏自主神经及内分泌功能恢复的随访指标.     

先天性心脏病患者血NT-proBNP浓度与肺动脉高压和导管封堵术的相关性

目的：研究先天性心脏病（CHD）患者血清氨基末端脑钠肽前体（NT-proBNP）浓度与肺动脉平均压（mPAP）的相关性.方法：62例行导管封堵治疗的CHD患者根据mPAP水平被分为四组：CHD不合并肺动脉高压（PAH）组（26例）、CHD合并轻度PAH组（17例）、CHD合并中度PAH组（12例）、CHD合并重度PAH组（7例）,同期选择20例健康体检者作为健康对照组.比较各组介入封堵术前后24h及3个月时的血清NT-proBNP浓度的变化并分析介入封堵术前NT-proBNP浓度与mPAP的关系.结果：与健康对照组相比,术前各CHD组血清NT-proBNP水平明显升高,且随着mPAP升高而显著升高[健康对照组（34.0±16.8）pg/ml比CHD无PAH组（68.0±20.2）pg/ml比轻度PAH组（116.7±43.5） pg/ml比中度PAH组（273.1±64.2）pg/ml比重度PAH组（326.5±50.2） pg/ml,P均＜0.01];直线相关分析显示：62例CHD患者术前血清NT-proBNP浓度与mPAP呈正相关（r=0.604,P=0.002）.各组术后24hNT-proBNP浓度较术前升高,但只有CHD不合并PAH组有统计学差异[（98.9±22.1） pg/ml比（68.0±20.2） pg/ml,P＜0.05],4组术后3个月NT-proBNP浓度较术前均有显著降低（P均＜0.01）.结论：先天性心脏病患者血清NT-proBNP浓度随肺动脉压力升高而逐渐升高,可作为先心病患者肺动脉高压程度以及预后判断的一个指标.     

Tei指数联合B型利钠肽原对起搏器患者术后心功能的评价

目的：探讨Tei指数和血浆N末端B型利钠肽原（NT-proBNP）水平对起搏器患者术后心功能评价的价值。方法：行永久起搏器植入术患者168例,起搏模式均为心室按需起搏（VVI）,术前,术后3个月、12个月行Tei指数、血清NT-proBNP、左室射血分数（LVEF）及E/A峰比值等检测,计算心室累积起搏（CumVP）比例（%）。按心室起搏比例区分为CumVP〈30%组（38例）,CumVP 30%～75%组（56例）,CumVP〉75%组（74例）3组。分析Tei指数与NT-proBNP在不同起搏指数患者之间的变化。结果：与术前比较,术后12个月Cum-VP〉75%组NT-proBNP[（124.88±12.56）ng/L比（168.42±32.46）ng/L]与Tei指数[（0.52±0.04）比（0.68±0.06）]显著升高（P〈0.05～〈0.01）,LVEF[（0.56±0.02）比（0.48±0.05）]显著降低（P〈0.05）;与术前比较,术后CumVP〈30%组上述指标的变化差异无显著性（P〉0.05）,CumVP 30%～75%组,Tei指数明显升高[（0.54±0.14）比（0.66±0.01）,P〈0.05],而BNP、LVEF变化差异无显著性（P〉0.05）。结论：起搏器患者心功能改变与起搏比例有关,N末端B型利钠肽原水平与Tei指数可作为评价术后心功能的指标。     

慢性重度心力衰竭患者血B型利钠肽浓度正常的临床意义探讨

目的 探讨慢性重度心力衰竭(心衰)患者出现血B型利钠肽(B-type natriuretic peptide,BNP)浓度正常的临床意义.方法 采用前瞻性对照研究的方法观察心功能Ⅲ～Ⅳ级的慢性重度心衰患者57例.血BNP浓度正常的13例患者为研究组(A组),血BNP浓度明显升高的44例为对照组(B组),分析两组患者的临床特点,判定血BNP浓度正常对于慢性重度心衰患者的意义.结果 两组患者的基线情况差异无统计学意义.A组的左室舒张末期内径大于B组[(70.56±4.33)mm与(63.73±3.75)mm,P＜0.05];A组的左室射血分数小于B组[(24.16±2.50)%与(28.49±2.63)%,P＜0.05].A组中能耐受美托洛尔的人数比例少于B组[(7/13)与(39/44),P＜0.05],耐受剂量低于B组[(12.5±6.25)mg/d与(24.20±11.22)mg/d,P＜0.05].两组血BNP浓度在稳定期各时间段无明显改变,但在慢性心衰急性发作与缓解后,A组无显著性改变[(74.03±11.18)ng/L与(71.38±11.68)ng/L,P＞0.05],而B组改变明显[(962.73±165.00)ng/L与(876.24±167.70)ng/L,P＜0.05].随访中,A组病死率高于B组(11/13与6/44,P＜0.05).Logistic多因素回归分析显示:血BNP降低为预测重度慢性心衰患者心原性死亡的独立危险因素(OR值45.488,95%可信区间5.322～388.791),P＜0.05.结论 慢性重度心衰患者出现血BNP浓度正常提示BNP分泌机制的耗竭和心脏功能的进一步恶化.     

中老年房间隔缺损患者介入治疗前心脏CT检查的价值

目的 评估心脏CT在筛查拟行房间隔缺损(ASD)封堵术中老年患者合并的心血管病变及指导封堵器选择方面的价值。方法 对63例拟行ASD封堵术的50 ～ 77( 56.87±5.79)岁患者行冠状动脉CT造影检查,了解心血管病变情况。随后行ASD三维重建,并测量ASD大小。分析经胸超声心动图与CT的ASD直径测量值之间以及ASD直径的CT测量值与ASD封堵器腰部直径之间的关系。结果 14例患者依据心脏CT检查结果调整了治疗方案：8例患者诊断为ASD合并冠心病,均行常规冠心病治疗,其中2例患者行经皮冠状动脉介入治疗和ASD封堵术,1例患者行冠状动脉旁路移植术和ASD封堵术,5例患者行药物治疗和ASD封堵术;2例患者因ASD后下缘残端不完整,而放弃介入治疗;1例患者超声心动图示ASD后下缘残端不完整,而CT显示缺损边缘尚可,行ASD封堵术;除外ASD 1例;合并部分型肺静异位引流(PAPVC)1例,行外科修补术;合并动脉导管未闭1例,行动脉导管未闭和ASD封堵术。经胸超声心动图与CT的ASD直径测量值之间呈正相关(r=0.80,P＜0.01),其线性回归方程为Y=0.84X +8.85(R2=0.63,P＜0.05)。ASD直径的CT测量值与ASD封堵器腰部直径之间呈正相关(r=0.92,P＜0.01),其线性回归方程为y=0.93X +4.78(R2=0.84,P＜0.05)。结论 对于拟行ASD封堵术的中老年患者,术前心脏CT检查可有效诊断合并的冠心病及其他心血管畸形,并能指导封堵器的选择。     

N末端B型利钠肽原对急性呼吸困难的鉴别诊断价值

目的：探讨血清N末端B型利钠肽原（NT-proBNP）水平对急性呼吸困难患者鉴别诊断的价值。方法：以胶体金法检测66例充血性心力衰竭（CHF）患者（CHF组）和38例有急性呼吸困难表现的非CHF患者（非CHF组）的血清NT-proBNP浓度,并与30例健康成人（正常对照组）作比较。结果：（1）CHF组NT—proBNP水平显著高于非CHF组和正常对照组[（2856．5±384．5）ng／L比（175．6±38．8）ng／L比（159．3±30．4）ng／L,P〈0．013;（2）CHF组NT-proBNP水平随NYHA心功能等级（Ⅱ,Ⅲ,Ⅳ级）的升高而显著升高[（2428．8±286．9）ng／L比（2815．6土318．8）ng／L比（3268．8±426．6）ng／L,P〈0．01];（3）Spearman相关分析显示,NT-proBNP与NYHA分级呈正相关（r=0．795,P〈0．01）,与左心室射血分数呈负相关（r=-0．745,P〈0．01）。结论：血清N末端B型利钠肽原水平对呼吸困难的鉴别诊断具有重要临床价值。     

ST段抬高型心肌梗死患者N末端脑利钠肽前体水平及其相关因素分析

目的探讨N末端脑利钠肽前体(NT-proBNP)在ST段抬高型心肌梗死患者的水平及其相关影响因素。方法入选诊断明确的急性ST段抬高型心肌梗死患者,并对NT-proBNP水平与可能的相关因素如性别、年龄、病史、心肌梗死范围、心房心室大小、冠状动脉病变情况、治疗情况以及肌钙蛋白I峰值等进行分析。结果在70例患者中未发现性别、高血压或糖尿病病史以及心房心室大小影响NT-proBNP水平。前壁心肌梗死或者心肌梗死累及部位更多的患者,NT-proBNP水平较高[累及前壁的心肌梗死(5116.7±2657.3)ng/L比非前壁心肌梗死(1150.5±916.1)ng/L,P=0.002;3部位受累患者(6269.3±3394.9)ng/L比2部位受累患者(4468.6±2259.8)ng/L或1部位受累患者(1282.1±946.4)ng/L,P=0.027]。年龄(r=0.335,P=0.009)和血肌酐水平(r=0.495,P=0.000)与NT-proBNP水平正相关,LVEF与其呈负相关(r=-0.343,P=0.01),差异有统计学意义。罪犯血管为前降支病变也与较高的NT-proBNP水平相关[前降支(4179.1±2728.2)ng/L比右冠状动脉或回旋支(670.7±359.2)ng/L,P=0.011]。接受直接冠心病介入治疗(PCI)者NT-proBNP水平较低[接受直接PCI(2690.8±1459.9)ng/L比未接受直接PCI的患者(6260.0±3191.2)ng/L,P=0.039]。结论 ST段抬高型前壁心肌梗死患者NT-proBNP较高,其升高程度与心电图判断的心肌受累范围相关,接受直接PCI的患者NT-proBNP水平较低。低LVEF与NT-proBNP水平升高的相关性不受年龄和血肌酐水平的影响。     

肌钙蛋白T联合血清氨基末端脑钠肽诊断儿童心衰的价值

目的：研究血浆肌钙蛋白T （cTnT）与 N 末端 B型利钠肽原（NT-proBNP）联合检测诊断儿童心力衰竭（HF）的价值。方法：选择我院73例儿童 HF患者为心衰组,另选儿童保健门诊75例健康儿童为健康对照组。检测两组的 cTnT、NT-proBNP浓度及左室射血分数（LVEF）,并比较。应用受试者工作特性曲线（ROC）分析 cT-nT和 NT-proBNP联用的诊断敏感度和特异度。结果：与健康对照组相比,心衰组 NT-proBNP [（2486.7±87.5） pmol/L比（3573.8±98.2）pmol/L]、cTnT [（0.03±0.01）ng/ml 比（0.35±0.09）ng/ml]浓度显著升高, LVEF [（70.8±5.2）％比（42.6±3.8）％]显著降低,P 均＜0.05;多元 Logistic回归分析显示,NT-proBNP为HF患童 LVEF的独立相关因素（OR＝1.006,P＝0.012）;NT-proBNP取值3200pmol/L、cTnT取值0.08ng/ml联合诊断儿童 HF的敏感性为89.5％,特异性为85.7％,ROC曲线下面积为0.795。结论：N末端 B型利钠肽原与心肌肌钙蛋白T联合检测对于儿童心力衰竭有较高的诊断价值。     

磷酸肌酸钠对冠心病心力衰竭患者左室射血分数及血浆氨基末端脑钠肽原的影响

目的观察磷酸肌酸钠对冠心病心力衰竭患者左室射血分数（LVEF）及血浆氨基末端脑钠肽原（NT-proBNP）的影响。方法冠心病心力衰竭患者96例,随机分为对照组48例和治疗组48例。对照组给予常规抗心衰药物如洋地黄制剂、利尿剂、ACEI、血管扩张剂及B受体阻滞剂等治疗;治疗组在此基础上加用磷酸肌酸钠2．0g,静脉滴注,1次／d,疗程2周。观察治疗前及治疗后患者的左室射血分数及血浆NT-proBNP水平。结果治疗组治疗后与治疗前相比LVEF明显提高[（45．2±5．8）％比（38．4±6-3）％,P〈0．05],血浆NT-pmBNP水平显著降低[（2317．5±128．5）ng／L比（398．4±78．5）ng／L,P〈0．05]。对照组治疗后LVEF亦有所提高[（41．1±6．1）％比（37．3±5．2）％],但差异无统计学意义（p〉O．05）,血浆NT—proBNP水平降低[（762．8±63．9）ng／L比（2512．4±136．2）ng／L,P〈0．05]。治疗后治疗组LVEF明显高于对照组[（45．2±5．8）％比（41．1±6．1）％,P〈0．05],而NT-proBNP水平显著低于对照组[（398．4±78．5）ng／L比（762．8±63．9）ng／L,P〈0．05]。结论磷酸肌酸钠治疗冠心病心力衰竭可改善患者心功能,提高左室射血分数,降低血浆NT-proBNP水平。